Ketorolac-13C6

Ketorolac-13C6 (RS37619-13C6) is 13C labeled Ketorolac. Ketorolac (RS37619) is a non-steroidal anti-inflammatory drug (NSAID), acting as a nonselective COX inhibitor, with IC50s of 20 nM for COX-1 and 120 nM for COX-2. Ketorolac tromethamine is used as 0.5% ophthalmic solution for the research of allergic conjunctivitis, cystoid macular edema, intraoperative miosis, and postoperative ocular inflammation and pain. Ketorolac tromethamine is also a DDX3 inhibitor that can be used for cancer research[1][4].

Product Specifications

Product Name Alternative

RS37619-13C6

UNSPSC

12352005

Target

Apoptosis; COX; Isotope-Labeled Compounds

Related Pathways

Apoptosis; Immunology/Inflammation; Others

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Cancer

Smiles

O=C(C1C2=CC=C(N2CC1)C([13C]3=[13C][13C]=[13C][13C]=[13C]3)=O)O

Molecular Formula

C9 13C6H8NO3

Molecular Weight

256.18

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Samal SK, et al. Ketorolac salt is a newly discovered DDX3 inhibitor to treat oral cancer. Sci Rep. 2015 Apr 28;5:9982.|[3]Waterbury LD, et al. Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. Curr Med Res Opin. 2006 Jun;22 (6) :1133-40.|[4]Fracon RN, et al. Treatment with paracetamol, ketorolac or etoricoxib did not hinder alveolar bone healing: a histometric study in rats. J Appl Oral Sci. 2010 Dec;18 (6) :630-4.|[5]Hsieh YC, et al. Intrathecal ketorolac pretreatment reduced spinal cord ischemic injury in rats. Anesth Analg. 2005 Apr;100 (4) :1134-9.